[Antitumor immune response of MHC class I chain-related gene A modified oral squamous cell carcinoma vaccine: an experimental study in mice]
Related Experiment Video
Updated: May 23, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Chao Li1, Fang-qiong Shi, Jie Wang
1Department of Oral and Maxillofacial Surgery, Xiangya Hospital. Changsha, China. lichao79568211@yahoo.cn
Purpose:
To investigate the vaccine potency of MHC class I chain-related gene A (MICA) modified oral squamous cell carcinoma cells.
Methods:
Oral squamous cell carcinoma Tb cells transfected with eukaryotic expression vector pEGFP-N1-MICA and overexpressing MICA protein were inactivated by 120Gy irradiation and vaccinated human peripheral blood leucocytes reconstituted SCID (Hu-PBL/SCID)mice via intra-peritoneal injection, and the non-transfected or blank vector transfected Tb cells were used as the controls. The inhibition effect on tumorigenicity of subcutaneously challenged Tb cells in vaccinated Hu-PBL/SCID mice was detected.The expression of NKG2D and the cytotoxicity in vitro to Tb cells of peripheral blood mononuclear cells (PBMCs) and spleen cells were measured by flow cytometry and lactate dehydrogenase (LDH) release assay. SPSS16.0 software package was used for statistical analysis.
Results:
MICA gene modified Tb tumor vaccine resulted in remarkable loss of tumor size and tumor weight in vaccinated Hu-PBL/SCID mice. Flow cytometry and lactate dehydrogenase (LDH) release assay showed MICA gene modified Tb tumor vaccine up-regulated the expression of NKG2D on PBMC and spleen cells and enhanced the cytotoxicity to tumor cells. Significant difference was found between MICA-transfected vaccine and non-transfected and blank vector-transfected vaccine (P<0.05).
Conclusions:
MICA gene modified oral squamous cell carcinoma vaccine can enhance the ability of antitumor immune response,and MICA may be considered as a promising immunotherapy target of oral squamous cell carcinoma.
Insights
This study shows that a vaccine using MHC class I chain-related gene A (MICA) modified oral squamous cell carcinoma cells effectively reduces tumor growth. The MICA vaccine enhances antitumor immune responses, highlighting MICA as a potential immunotherapy target for oral cancer.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Oral squamous cell carcinoma (OSCC) is a prevalent malignancy.
- Developing effective immunotherapies for OSCC remains a critical challenge.
- MHC class I chain-related gene A (MICA) plays a role in immune surveillance.
Purpose of the Study:
- To evaluate the vaccine potency of OSCC cells genetically modified to overexpress MICA.
- To assess the potential of MICA as a therapeutic target for OSCC.
Main Methods:
- OSCC cells (Tb) were transfected to overexpress MICA.
- Inactivated MICA-transfected cells were used as a vaccine in human peripheral blood leucocytes reconstituted SCID (Hu-PBL/SCID) mice.
- Tumorigenicity, NKG2D expression, and cytotoxicity of immune cells were measured.
- Standard statistical analysis was employed.
Main Results:
- MICA-modified OSCC cell vaccines significantly reduced tumor size and weight in vaccinated mice.
- The vaccine increased NKG2D expression on peripheral blood mononuclear cells (PBMCs) and spleen cells.
- Enhanced in vitro cytotoxicity against tumor cells was observed, with significant differences compared to control groups (P<0.05).
Conclusions:
- MICA gene-modified OSCC vaccines demonstrate enhanced antitumor immune responses.
- MICA represents a promising target for immunotherapy in oral squamous cell carcinoma.
- Further investigation into MICA-based therapies for OSCC is warranted.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
